HER-2 S310Y
|
Gastric Cancer
|
HER-2 S310Y
|
Gastric Cancer
|
trastuzumab + tucatinib Sensitive: D – Preclinical
|
trastuzumab + tucatinib Sensitive: D – Preclinical
|
HER-2 S310Y
|
Gastric Cancer
|
HER-2 S310Y
|
Gastric Cancer
|
tucatinib Sensitive: D – Preclinical
|
tucatinib Sensitive: D – Preclinical
|
HER-2 S310Y
|
CRC
|
HER-2 S310Y
|
CRC
|
trastuzumab + tucatinib Sensitive: D – Preclinical
|
trastuzumab + tucatinib Sensitive: D – Preclinical
|
HER-2 S310Y
|
CRC
|
HER-2 S310Y
|
CRC
|
tucatinib Sensitive: D – Preclinical
|
tucatinib Sensitive: D – Preclinical
|
HER-2 S310Y
|
NSCLC
|
HER-2 S310Y
|
NSCLC
|
trastuzumab + tucatinib Sensitive: D – Preclinical
|
trastuzumab + tucatinib Sensitive: D – Preclinical
|
HER-2 S310Y
|
NSCLC
|
HER-2 S310Y
|
NSCLC
|
tucatinib Sensitive: D – Preclinical
|
tucatinib Sensitive: D – Preclinical
|